EBS has been the topic of several other reports. Cowen decreased their price objective on shares of Emergent BioSolutions from $40.00 to $30.00 in a report on Friday. Chardan Capital decreased their price objective on shares of Emergent BioSolutions from $75.00 to $65.00 in a report on Friday. Benchmark upgraded shares of Emergent BioSolutions from a hold rating to a buy rating and set a $77.00 price objective on the stock in a report on Thursday, January 20th. Zacks Investment Research upgraded shares of Emergent BioSolutions from a strong sell rating to a hold rating and set a $45.00 price objective on the stock in a report on Friday, February 18th. Finally, Cantor Fitzgerald lowered shares of Emergent BioSolutions from an overweight rating to a neutral rating in a report on Friday. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Emergent BioSolutions presently has an average rating of Hold and a consensus target price of $48.86.
NYSE:EBS opened at $32.38 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.40 and a quick ratio of 2.46. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of 11.13 and a beta of 0.88. The company’s 50-day moving average is $40.91 and its two-hundred day moving average is $43.56. Emergent BioSolutions has a 1-year low of $29.88 and a 1-year high of $68.03.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Eaton Vance Management increased its stake in Emergent BioSolutions by 39.8% during the 4th quarter. Eaton Vance Management now owns 2,745 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 782 shares during the period. Cutler Group LP increased its position in shares of Emergent BioSolutions by 250.0% in the 1st quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 500 shares during the last quarter. Covestor Ltd purchased a new stake in shares of Emergent BioSolutions in the 4th quarter valued at approximately $49,000. Schroder Investment Management Group purchased a new stake in shares of Emergent BioSolutions in the 4th quarter valued at approximately $54,000. Finally, First Bank & Trust increased its position in shares of Emergent BioSolutions by 32.3% in the 4th quarter. First Bank & Trust now owns 1,850 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 452 shares during the last quarter. 85.51% of the stock is currently owned by hedge funds and other institutional investors.
About Emergent BioSolutions (Get Rating)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.